Travere (TVTX) EVP/CMO Inrig Jula Sells Shares After Exercising Options

What Happened

• Inrig Jula, EVP, Head of R&D & Chief Medical Officer of Travere Therapeutics (TVTX), exercised 32,395 option-derived shares (reported at $8.93/share, cost $289,287) on 2026-09-15 and sold a total of 44,674 common shares the same day in multiple open-market transactions, generating aggregate proceeds of approximately $2.79 million. The filing shows both the acquisition via exercise and same‑day sales, consistent with an exercise-and-sell (cashless-style) sequence.

Key Details

• Transaction date (reporting period): 2026-09-15; Form 4 filed: 2026-09-17 (appears timely).
• Option exercise: 32,395 shares acquired at $8.93 each (total ~$289,287).
• Open-market sales (total sold = 44,674 shares; total proceeds ≈ $2,785,021):
  • 25,390 shares @ $62.02 (proceeds $1,574,604) — F1: sale pursuant to 10b5‑1 plan (adopted 6/16/2026).
  • 17,284 shares @ $62.62 (proceeds $1,082,397).
  • 1,600 shares @ $63.69 (proceeds $101,896).
  • 400 shares @ $65.31 (proceeds $26,124).
• Footnotes: F2–F4 provide weighted-average sale prices and price ranges for the grouped sales; full per-price breakdown is available upon request. F5 describes the original option vesting schedule.
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context

• These transactions were executed under a written 10b5‑1 trading plan (F1), which is a pre‑arranged plan that can explain routine sales and is not, by itself, an indicator of current insider sentiment. The combination of an option exercise and near-immediate sales is common when insiders cover exercise costs or taxes; the filing’s derivative entries reflect the exercise/conversion event followed by dispositions. Purchases generally convey stronger bullish signals than planned sales.